Showing results (231-240 of 247) with videos related to
Sort By:
Pageof 25
Oncotarget|January 26, 2023
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)Leo I Gordon, Reem Karmali, Jason B Kaplan, et al.The Lancet. Oncology|July 19, 2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S Falchook, Karl D Lewis, Jeffrey R Infante, et al.Breast Cancer Research and Treatment|May 17, 2017
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancerDenise A Yardley, Edward R Arrowsmith, Brooke R Daniel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid TumorsJoaquin Mateo, Gopinath Ganji, Charlotte Lemech, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibGeorgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid TumorsTae Won Kim, Howard A Burris, Maria J de Miguel Luken, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian CancerDavid E Gerber, Jeffrey R Infante, Michael S Gordon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.Cancer Discovery|August 8, 2024
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 StudyJustin F Gainor, Manish R Patel, Jeffrey S Weber, et al.Cancer Discovery|January 30, 2013
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvementJosep Tabernero, Geoffrey I Shapiro, Patricia M LoRusso, et al.Pageof 25